Advanced Enzyme Technologies (ADVENZYMES) investor relations material

Executive summary

• Q3 FY26 revenue was INR 1,719 million, up 2% year-over-year but down 7% sequentially; nine-month revenue grew 15% year-over-year to INR 5,424 million.

• Q3 EBITDA margin declined to 29% from 33% last year; EBITDA was INR 494 million (-11% YoY, -18% QoQ); profit after tax rose 11% YoY to INR 432 million.

• Human Healthcare contributed 56% of Q3 revenue but declined 6% YoY; Animal Healthcare contributed 14% and grew 22% YoY; Bioprocessing contributed 9% and grew 13% YoY.

• Board approved collaboration for a Group Captive Wind Power Plant via SPV, with up to 26% equity investment; discontinued plans for a group captive solar power project.

• Exceptional item of INR 112 million impacted Q3 FY26 results, mainly due to reversal of provision for US lawsuit and Indian labour code changes.

Financial highlights

• Q3 FY26 revenue: INR 1,719 million (+2% YoY, -7% QoQ); nine-month revenue: INR 5,424 million (+15% YoY).

• Q3 EBITDA: INR 494 million (-11% YoY, -18% QoQ); nine-month EBITDA: INR 1,658 million (+11% YoY).

• Q3 profit after tax: INR 432 million (+11% YoY, -3% QoQ); nine-month PAT: INR 1,284 million (+20% YoY).

• Consolidated net profit for Q3 FY26: INR 582.91 million, nine-month net profit: INR 1,727.32 million.

• EPS for Q3 FY26 was INR 3.80, up 13% YoY.

Outlook and guidance

• Management expects strong growth trajectory to persist across all business segments, targeting 13–15% annual revenue growth over the next three to five years.

• Focus areas include expanding animal nutrition, probiotics, bio-catalysis, and baking solutions, with new product launches and global distribution.

• U.S. market outlook improving with more inquiries and normalization expected as tariffs moderate.

• Continued investment in R&D, inorganic expansion, and strategic partnerships are highlighted as growth drivers.

• Expansion into renewable energy through wind power investment.